Leerink Partnrs Has Pessimistic View of EW FY2025 Earnings

Edwards Lifesciences Co. (NYSE:EW) – Equities researchers at Leerink Partnrs lowered their FY2025 earnings per share (EPS) estimates for shares of Edwards Lifesciences in a research report issued on Wednesday, February 12th. Leerink Partnrs analyst M. Kratky now expects that the medical research company will post earnings of $2.41 per share for the year, down from their prior forecast of $2.43. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.56 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ FY2026 earnings at $2.76 EPS and FY2027 earnings at $3.23 EPS.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%.

EW has been the topic of several other research reports. Citigroup boosted their target price on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their price objective for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Royal Bank of Canada restated an “outperform” rating and issued a $85.00 target price on shares of Edwards Lifesciences in a report on Wednesday. Sanford C. Bernstein upgraded shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Finally, Morgan Stanley raised their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $79.86.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $75.83 on Thursday. The firm has a fifty day simple moving average of $72.51 and a two-hundred day simple moving average of $69.36. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a market capitalization of $44.72 billion, a PE ratio of 10.94, a P/E/G ratio of 3.64 and a beta of 1.10.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the completion of the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at $1,717,841.12. This trade represents a 9.73 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.29% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Edwards Lifesciences

A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in Edwards Lifesciences by 10.4% in the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock worth $5,117,845,000 after purchasing an additional 6,537,494 shares in the last quarter. Wellington Management Group LLP boosted its stake in Edwards Lifesciences by 5.3% during the 4th quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company’s stock valued at $2,458,601,000 after purchasing an additional 1,678,154 shares during the last quarter. State Street Corp increased its holdings in shares of Edwards Lifesciences by 1.0% in the 3rd quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock worth $1,733,270,000 after purchasing an additional 256,538 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Edwards Lifesciences by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company’s stock worth $1,007,520,000 after purchasing an additional 126,194 shares during the last quarter. Finally, Fisher Asset Management LLC lifted its holdings in shares of Edwards Lifesciences by 7.7% during the fourth quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company’s stock valued at $723,664,000 after purchasing an additional 696,965 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.